Medicare beneficiaries who use insulin now have a broader path to continuous glucose monitors, a shift that could make daily finger-stick test strips obsolete for a significant share of the program’s diabetic population. A 2023 revision to the Local Coverage Determination for glucose monitors removed the prior requirement that a patient administer insulin three or more times per day to qualify. The change also extended eligibility to certain non-insulin users with a documented history of problematic low blood sugar, opening the door for people previously locked out of the technology.
How the 2023 LCD revision widened CGM access under Part B
Before the revision, Medicare’s coverage rules for continuous glucose monitors effectively restricted the devices to people on intensive insulin regimens. The glucose monitor policy, revised in 2023 by the Durable Medical Equipment Medicare Administrative Contractors, dropped that threshold. The finalized policy now qualifies beneficiaries who take insulin fewer than three times per day, a population that had been left to rely entirely on traditional blood glucose strips and lancets.
The practical result is straightforward: a Medicare enrollee whose clinician prescribes a CGM no longer needs to prove a multi-injection insulin schedule. A clinician’s order plus documented clinical need, whether insulin use or a history of problematic hypoglycemia, satisfies the coverage criteria. Suppliers must still obtain Pricing, Data Analysis and Coding verification, the administrative step that confirms a device meets Medicare’s standards for therapeutic CGM coverage under Part B durable medical equipment rules, according to the CMS guidance on glucose monitors.
For the people affected, the difference is tangible. A CGM sensor, worn on the skin and replaced every week or two, transmits glucose readings automatically. That replaces the routine of pricking a finger several times a day, buying strips in bulk, and managing the waste. The technology has been covered by Medicare since 2017, but the earlier eligibility rules kept it out of reach for many enrollees whose insulin regimens did not meet the frequency cutoff.
What the rulemaking record shows about expanded eligibility
The CMS rulemaking trail spells out the rationale. The DME MAC response to comments on the LCD revision confirms that the finalized determination expands coverage to people using insulin fewer than three times per day and to certain non-insulin users with problematic hypoglycemia. That language directly addresses the two groups most affected by the old restriction: patients on basal-only insulin and those on oral medications who experience dangerous glucose drops.
Commenters had argued that the original three-injection requirement was out of step with evolving diabetes care, where long-acting insulin and non-insulin drugs can still carry a risk of severe lows. In revising the LCD, the contractors acknowledged that CGMs can improve safety and self-management for people who are not on intensive insulin therapy but remain vulnerable to hypoglycemia. The updated criteria therefore align coverage more closely with clinical risk rather than with a simple count of daily injections.
One question the policy record does not answer is scale. CMS has not published post-revision enrollment figures or claims-volume data showing how many new beneficiaries have actually received CGMs since the LCD took effect. Without that data, the hypothesis that broadened eligibility will produce a measurable decline in Part B spending on blood glucose test strips within 18 months cannot yet be confirmed or rejected. Aggregated claims releases from CMS would be the first place such a shift would appear, but no such dataset has surfaced in the public record as of mid-2026.
What the coverage change means for beneficiaries
For individual enrollees, the expanded rules translate into a clearer path from medical need to covered device. Under Medicare Part B, therapeutic CGMs are treated as durable medical equipment when certain conditions are met, including use with compatible supplies and receivers. Beneficiaries still need a face-to-face visit or telehealth encounter where a clinician documents diabetes, the need for frequent glucose monitoring, and a treatment plan that will use the CGM data. But they no longer face a categorical exclusion based solely on how many times per day they inject insulin.
Medicare’s beneficiary-facing materials emphasize that covered devices must be approved for use without routine finger sticks and obtained from enrolled suppliers. The official coverage page notes that, when requirements are met, Part B helps pay for both the monitor and related supplies, subject to standard deductibles and coinsurance. For many people living on fixed incomes, that distinction-between full out-of-pocket payment and cost sharing under Part B-can determine whether they adopt the technology at all.
Clinicians and suppliers, meanwhile, must navigate the detailed coding and documentation framework that sits behind the seemingly simple expansion. The CMS policy article on glucose monitors explains how products are categorized, which models qualify as therapeutic CGMs, and how claims should be submitted. That administrative backbone ensures that the broader eligibility criteria translate into consistent coverage decisions across Medicare’s regions, rather than a patchwork of interpretations.
As the revised LCD continues to shape access, researchers and policymakers will be watching for downstream effects: whether emergency visits for severe hypoglycemia decline, how medication patterns shift, and what happens to spending on older testing technologies. For now, the most immediate impact is at the patient level, where a previously rigid rule has given way to a more flexible standard that better reflects the realities of living with diabetes under Medicare.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
